- Home
- SNDX
as 06-20-2025 4:00pm EST
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 1.1B | IPO Year: | 2016 |
| Target Price: | $35.91 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.86 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.58 - $25.07 | Next Earning Date: | 07-31-2025 |
| Revenue: | $43,722,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 426.77% | Revenue Growth (next year): | 98.31% |
Stock Insider Trading Activity of Syndax Pharmaceuticals Inc. (SNDX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Katkin Keith | SNDX | Director | May 19 '25 | Buy | $9.11 | 10,000 | $91,120.00 | 100,000 | |
| Huber Martin H. Jr. | SNDX | Director | May 19 '25 | Buy | $8.99 | 5,000 | $44,950.00 | 79,000 | |
| Botwood Nicholas A.J. | SNDX | Head of R&D, CMO | May 16 '25 | Buy | $9.00 | 11,765 | $105,826.17 | 35,165 |
Latest Syndax Pharmaceuticals Inc. News
SNDX Breaking Stock News: Dive into SNDX Ticker-Specific Updates for Smart Investing
TipRanks
7 days ago
Syndax reports publication of revumenib data from BEAT AML trial
GlobeNewswire
8 days ago
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025
GlobeNewswire
9 days ago
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025
GlobeNewswire
15 days ago
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
23 days ago
Syndax Announces Participation in June Investor Conferences
GlobeNewswire
a month ago
Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)
MT Newswires
a month ago
Syndax Pharmaceuticals Appoints Nicholas Botwood Chief Medical Officer
GlobeNewswire
a month ago
Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer
Compare SNDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SNDX Syndax Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.